<p>Twist Bioscience Corporation (NASDAQ:TWST - 獲取免費報告) 的股價在週一的午盤交易中下跌了 4.4%，原因是內部人士出售股票。該公司的股價最低跌至 29.89 美元，最後交易價格為 29.82 美元。在午盤交易中，共成交 511,249 股，較平均交易量 1,276,625 股下降了 60%。該股票此前收盤價為 31.19 美元。</p>
<p>獲取 <strong>Twist Bioscience</strong> 的提醒：</p>
<p>具體來説，首席財務官亞當·拉波尼斯（Adam Laponis）在 10 月 9 日（星期四）進行了一筆交易，出售了 2,517 股股票。這些股票的平均售價為 32.92 美元，總價值為 82,859.64 美元。交易完成後，首席財務官直接持有公司 91,525 股股票，價值約為 3,013,003 美元。這筆交易代表了他們持股比例的 2.68% 的減少。該出售在向美國證券交易委員會（SEC）提交的文件中披露，文件可通過 SEC 網站訪問。此外，首席財務官亞當·拉波尼斯在 10 月 8 日（星期三）進行了一筆交易，出售了 3,000 股股票。這些股票的平均售價為 31.15 美元，總交易額為 93,450.00 美元。交易完成後，首席財務官直接持有公司 94,042 股股票，價值約為 2,929,408.30 美元。這筆交易代表了他們持股比例的 3.09% 的減少。該出售的披露信息可以在此找到。在其他 Twist Bioscience 的新聞中，內部人士丹尼斯·喬（Dennis Cho）在 10 月 6 日（星期一）進行了一筆交易，出售了 3,876 股股票。這些股票的平均售價為 32.19 美元，總價值為 124,768.44 美元。交易完成後，內部人士直接持有公司 98,710 股股票，價值約為 3,177,474.90 美元。這筆交易代表了他們持股比例的 3.78% 的減少。該出售在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。</p>
<h2>分析師評級升級與降級</h2>
<p>TWST 已經成為幾份研究報告的主題。Evercore ISI 在 10 月 7 日（星期二）的研究報告中將 Twist Bioscience 的目標股價從 46.00 美元下調至 42.00 美元，並對該股票給予 “跑贏大盤” 的評級。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Twist Bioscience 的 “賣出（d-）” 評級。巴克萊在 10 月 2 日（星期四）的研究報告中將 Twist Bioscience 的目標股價從 45.00 美元下調至 40.00 美元，並對該股票給予 “增持” 的評級。最後，Cowen 在 8 月 4 日（星期一）的研究報告中重申了對 Twist Bioscience 的 “買入” 評級。九位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 48.50 美元。</p>
<p><strong>獲取我們關於 Twist Bioscience 的最新研究報告</strong></p>
<h2>Twist Bioscience 價格表現</h2>
<p>該股票的市值為 18 億美元，市盈率為-20.56，貝塔值為 2.38。該公司的 50 日簡單移動平均線為 27.63 美元，200 日簡單移動平均線為 32.53 美元。該公司的債務與股本比率為 0.03，速動比率為 3.60，流動比率為 3.90。</p>
<p>Twist Bioscience (NASDAQ:TWST - 獲取免費報告) 最近於 8 月 4 日（星期一）發佈了其財報。該公司報告季度每股收益（EPS）為-0.47 美元，超出分析師一致預期的-0.54 美元，超出幅度為 0.07 美元。Twist Bioscience 的淨利潤率為-23.51%，股本回報率為-29.03%。該公司季度收入為 9,606 萬美元，而一致預期為 9,552 萬美元。Twist Bioscience 已將其 2025 財年的指引設定為每股收益。2025 財年第四季度的指引為每股收益。研究分析師預計 Twist Bioscience Corporation 將在本年度發佈-2.12 美元的每股收益。</p>
<h2>機構資金流入與流出</h2>
<p>機構投資者最近對該公司的持倉進行了調整。瑞銀資產管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度將其在 Twist Bioscience 的持倉增加了 186.1%。瑞銀資產管理現在持有該公司 2,442,262 股股票，價值 95,883,000 美元，此前在上一季度增持了 1,588,587 股。EdgePoint Investment Group Inc.在第二季度將其在 Twist Bioscience 的持倉增加了 114.3%。EdgePoint Investment Group Inc.現在持有該公司 2,385,942 股股票，價值 87,779,000 美元，此前在上一季度增持了 1,272,732 股。Nuveen LLC 在第一季度獲得了 Twist Bioscience 的新股份，價值 31,960,000 美元。ARK 投資管理（ARK Investment Management LLC）在第一季度將其在 Twist Bioscience 的持倉增加了 11.5%。ARK 投資管理現在持有該公司 6,241,595 股股票，價值 245,045,000 美元，此前在上一季度增持了 645,730 股。最後，Balyasny 資產管理公司（Balyasny Asset Management L.P.）在第二季度將其在 Twist Bioscience 的持倉增加了 934.0%。Balyasny 資產管理公司現在持有該公司 628,241 股股票，價值 23,113,000 美元，此前在上一季度增持了 567,481 股。</p>
<h2>關於 Twist Bioscience</h2>
<p>（獲取免費報告）</p>
<p>Twist Bioscience Corporation 從事合成 DNA 產品的製造和銷售。該公司提供用於治療、診斷、化學/材料、食品/農業、數據存儲以及生物技術、製藥、工業化學和農業公司以及學術實驗室的各種應用的合成基因和基因片段；用於靶向 NGS、CRISPR 基因編輯、誘變實驗、DNA 摺紙、DNA 計算、DNA 數據存儲等應用的寡核苷酸池；以及專注於藥物發現和開發的客户所需的免疫球蛋白 G 蛋白。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Twist Bioscience</li>
<li>製造業股票投資</li>
<li>Absci 可能成為 AI 生物技術未來的兩個理由，以及一個風險</li>
<li>內部交易可能不會告訴你你想的那樣</li>
<li>Applied Digital 的空頭頭寸被擠壓——接下來怎麼辦？</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>Levi Strauss 股票預計在 2026 年達到新高</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Twist Bioscience 嗎？</h2>
<p>在你考慮 Twist Bioscience 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Twist Bioscience 並不在名單上。</p>
<p>雖然 Twist Bioscience 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TWST

<p>Twist Bioscience（納斯達克代碼：TWST）股價因內部人士拋售下跌 4.4%，至 29.82 美元，首席財務官 Adam Laponis 以 32.92 美元出售了 2,517 股，以 31.15 美元出售了 3,000 股。分析師已下調該股票評級，Evercore ISI 將其目標價從 46 美元下調至 42 美元。該股票市值為 18 億美元，每股收益為-0.47。機構投資者增加了持股，瑞銀資產管理公司將其持倉增加了 186.1%</p>

<p>Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s stock price traded down 4.4% during mid-day trading on Monday following insider selling activity. The company traded as low as $29.89 and last traded at $29.82. 511,249 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 1,276,625 shares. The stock had previously closed at $31.19.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation (NASDAQ:TWST - 獲取免費報告) 的股價在週一的午盤交易中下跌了 4.4%，原因是內部人士出售股票。該公司的股價最低跌至 29.89 美元，最後交易價格為 29.82 美元。在午盤交易中，共成交 511,249 股，較平均交易量 1,276,625 股下降了 60%。該股票此前收盤價為 31.19 美元。</p>
</div><p>Get <strong>Twist Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Twist Bioscience</strong> 的提醒：</p>
</div><p>Specifically, CFO Adam Laponis sold 2,517 shares of the stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $32.92, for a total value of $82,859.64. Following the completion of the transaction, the chief financial officer directly owned 91,525 shares of the company's stock, valued at approximately $3,013,003. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Laponis sold 3,000 shares of the stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $31.15, for a total transaction of $93,450.00. Following the completion of the transaction, the chief financial officer directly owned 94,042 shares of the company's stock, valued at approximately $2,929,408.30. This trade represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Twist Bioscience news, insider Dennis Cho sold 3,876 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the completion of the transaction, the insider directly owned 98,710 shares of the company's stock, valued at approximately $3,177,474.90. This trade represents a 3.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>具體來説，首席財務官亞當·拉波尼斯（Adam Laponis）在 10 月 9 日（星期四）進行了一筆交易，出售了 2,517 股股票。這些股票的平均售價為 32.92 美元，總價值為 82,859.64 美元。交易完成後，首席財務官直接持有公司 91,525 股股票，價值約為 3,013,003 美元。這筆交易代表了他們持股比例的 2.68% 的減少。該出售在向美國證券交易委員會（SEC）提交的文件中披露，文件可通過 SEC 網站訪問。此外，首席財務官亞當·拉波尼斯在 10 月 8 日（星期三）進行了一筆交易，出售了 3,000 股股票。這些股票的平均售價為 31.15 美元，總交易額為 93,450.00 美元。交易完成後，首席財務官直接持有公司 94,042 股股票，價值約為 2,929,408.30 美元。這筆交易代表了他們持股比例的 3.09% 的減少。該出售的披露信息可以在此找到。在其他 Twist Bioscience 的新聞中，內部人士丹尼斯·喬（Dennis Cho）在 10 月 6 日（星期一）進行了一筆交易，出售了 3,876 股股票。這些股票的平均售價為 32.19 美元，總價值為 124,768.44 美元。交易完成後，內部人士直接持有公司 98,710 股股票，價值約為 3,177,474.90 美元。這筆交易代表了他們持股比例的 3.78% 的減少。該出售在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>TWST has been the topic of several research reports. Evercore ISI lowered their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an &#34;outperform&#34; rating on the stock in a research report on Tuesday, October 7th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Barclays decreased their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an &#34;overweight&#34; rating on the stock in a research report on Thursday, October 2nd. Finally, Cowen restated a &#34;buy&#34; rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $48.50.</p>
<div class="lb-trans"><p>TWST 已經成為幾份研究報告的主題。Evercore ISI 在 10 月 7 日（星期二）的研究報告中將 Twist Bioscience 的目標股價從 46.00 美元下調至 42.00 美元，並對該股票給予 “跑贏大盤” 的評級。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Twist Bioscience 的 “賣出（d-）” 評級。巴克萊在 10 月 2 日（星期四）的研究報告中將 Twist Bioscience 的目標股價從 45.00 美元下調至 40.00 美元，並對該股票給予 “增持” 的評級。最後，Cowen 在 8 月 4 日（星期一）的研究報告中重申了對 Twist Bioscience 的 “買入” 評級。九位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 48.50 美元。</p>
</div><p><strong>Get Our Latest Research Report on Twist Bioscience</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Twist Bioscience 的最新研究報告</strong></p>
</div><h2>Twist Bioscience Price Performance</h2>
<div class="lb-trans"><h2>Twist Bioscience 價格表現</h2>
</div><p>The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -20.56 and a beta of 2.38. The business's 50 day simple moving average is $27.63 and its 200-day simple moving average is $32.53. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90.</p>
<div class="lb-trans"><p>該股票的市值為 18 億美元，市盈率為-20.56，貝塔值為 2.38。該公司的 50 日簡單移動平均線為 27.63 美元，200 日簡單移動平均線為 32.53 美元。該公司的債務與股本比率為 0.03，速動比率為 3.60，流動比率為 3.90。</p>
</div><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.</p>
<div class="lb-trans"><p>Twist Bioscience (NASDAQ:TWST - 獲取免費報告) 最近於 8 月 4 日（星期一）發佈了其財報。該公司報告季度每股收益（EPS）為-0.47 美元，超出分析師一致預期的-0.54 美元，超出幅度為 0.07 美元。Twist Bioscience 的淨利潤率為-23.51%，股本回報率為-29.03%。該公司季度收入為 9,606 萬美元，而一致預期為 9,552 萬美元。Twist Bioscience 已將其 2025 財年的指引設定為每股收益。2025 財年第四季度的指引為每股收益。研究分析師預計 Twist Bioscience Corporation 將在本年度發佈-2.12 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. EdgePoint Investment Group Inc. lifted its stake in shares of Twist Bioscience by 114.3% in the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock worth $87,779,000 after buying an additional 1,272,732 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Twist Bioscience in the first quarter worth $31,960,000. ARK Investment Management LLC raised its stake in Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its stake in Twist Bioscience by 934.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company's stock valued at $23,113,000 after purchasing an additional 567,481 shares during the last quarter.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。瑞銀資產管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度將其在 Twist Bioscience 的持倉增加了 186.1%。瑞銀資產管理現在持有該公司 2,442,262 股股票，價值 95,883,000 美元，此前在上一季度增持了 1,588,587 股。EdgePoint Investment Group Inc.在第二季度將其在 Twist Bioscience 的持倉增加了 114.3%。EdgePoint Investment Group Inc.現在持有該公司 2,385,942 股股票，價值 87,779,000 美元，此前在上一季度增持了 1,272,732 股。Nuveen LLC 在第一季度獲得了 Twist Bioscience 的新股份，價值 31,960,000 美元。ARK 投資管理（ARK Investment Management LLC）在第一季度將其在 Twist Bioscience 的持倉增加了 11.5%。ARK 投資管理現在持有該公司 6,241,595 股股票，價值 245,045,000 美元，此前在上一季度增持了 645,730 股。最後，Balyasny 資產管理公司（Balyasny Asset Management L.P.）在第二季度將其在 Twist Bioscience 的持倉增加了 934.0%。Balyasny 資產管理公司現在持有該公司 628,241 股股票，價值 23,113,000 美元，此前在上一季度增持了 567,481 股。</p>
</div><h2>About Twist Bioscience</h2>
<div class="lb-trans"><h2>關於 Twist Bioscience</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation 從事合成 DNA 產品的製造和銷售。該公司提供用於治療、診斷、化學/材料、食品/農業、數據存儲以及生物技術、製藥、工業化學和農業公司以及學術實驗室的各種應用的合成基因和基因片段；用於靶向 NGS、CRISPR 基因編輯、誘變實驗、DNA 摺紙、DNA 計算、DNA 數據存儲等應用的寡核苷酸池；以及專注於藥物發現和開發的客户所需的免疫球蛋白 G 蛋白。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Twist Bioscience</li>
<li>Manufacturing Stocks Investing</li>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Applied Digital’s Shorts Got Squeezed—Now What?</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Levi Strauss Stock Set to Reach New Highs in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Twist Bioscience</li>
<li>製造業股票投資</li>
<li>Absci 可能成為 AI 生物技術未來的兩個理由，以及一個風險</li>
<li>內部交易可能不會告訴你你想的那樣</li>
<li>Applied Digital 的空頭頭寸被擠壓——接下來怎麼辦？</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>Levi Strauss 股票預計在 2026 年達到新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Twist Bioscience 嗎？</h2>
</div><p>Before you consider Twist Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Twist Bioscience 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Twist Bioscience 並不在名單上。</p>
</div><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Twist Bioscience 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Twist Bioscience（NASDAQ:TWST）股價因內部人士出售股票下跌 4.4%